To the Editor: Dr. Steele and his co-workers deserve plaudits for their well-designed double-blind trial of dialyzable transfer factor in the prevention of varicella–zoster infections in childhood leukemia (August 14 issue). I wish to point out that the cited leishmania study of Sharma et al. is not the only published double-blind controlled trial to demonstrate the efficacy of transfer factor; our placebo-controlled double-blind trial of this agent in chronic aggressive hepatitis B was published last year.* In addition, I wonder whether Dr. Steele and the rest of us in the fields of infectious disease and immunology should refer to our.
ASJC Scopus subject areas